3.30
-0.63 (-16.03%)
Previous Close | 3.93 |
Open | 3.94 |
Volume | 180,702 |
Avg. Volume (3M) | 43,858 |
Market Cap | 49,371,628 |
Price / Sales | 1.15 |
Price / Book | 1.72 |
52 Weeks Range | |
Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
Profit Margin | -7.98% |
Operating Margin (TTM) | 11.03% |
Diluted EPS (TTM) | -0.240 |
Quarterly Revenue Growth (YOY) | 37.80% |
Total Debt/Equity (MRQ) | 36.84% |
Current Ratio (MRQ) | 1.25 |
Operating Cash Flow (TTM) | 5.42 M |
Levered Free Cash Flow (TTM) | 3.56 M |
Return on Assets (TTM) | -2.70% |
Return on Equity (TTM) | -11.86% |
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
Stock | Cumberland Pharmaceuticals Inc. | - | - |
AIStockmoo Score
Analyst Consensus | -2.0 |
Insider Activity | NA |
Price Volatility | 1.0 |
Technical Moving Averages | -2.5 |
Technical Oscillators | -0.5 |
Average | -1.00 |
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Investment Style | Small Value |
% Held by Insiders | 41.54% |
% Held by Institutions | 28.76% |
Ownership
Name | Date | Shares Held |
---|---|---|
Berkshire Asset Management Llc/Pa | 31 Mar 2025 | 153,810 |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
23 Jun 2025 | Announcement | Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference |
27 May 2025 | Announcement | NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS |
13 May 2025 | Announcement | CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH |
06 May 2025 | Announcement | Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025 |
29 Apr 2025 | Announcement | CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |